WO2017013172A1 - Nouveaux inhibiteurs de la glycoprotéine p - Google Patents

Nouveaux inhibiteurs de la glycoprotéine p Download PDF

Info

Publication number
WO2017013172A1
WO2017013172A1 PCT/EP2016/067291 EP2016067291W WO2017013172A1 WO 2017013172 A1 WO2017013172 A1 WO 2017013172A1 EP 2016067291 W EP2016067291 W EP 2016067291W WO 2017013172 A1 WO2017013172 A1 WO 2017013172A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cell
ikr
pgp
cells
Prior art date
Application number
PCT/EP2016/067291
Other languages
English (en)
Inventor
Roland Brock
Marco Emanuele FAVRETTO
Original Assignee
Stichting Katholieke Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Katholieke Universiteit filed Critical Stichting Katholieke Universiteit
Publication of WO2017013172A1 publication Critical patent/WO2017013172A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Definitions

  • the present invention relates to the field of medicine, specifically the field of cancer treatment.
  • a new class of molecules is provided that inhibits P-glycoprotein activity.
  • the P-glycoprotein is a transmembrane protein belonging to the class of ABC transporters.
  • the protein acts as a cytoplasmic pump to efflux substances from the cell, and its efflux mechanism requires energy derived from the hydrolysis of ATP to ADP.
  • the substrates are potentially toxic xeno -metabolites (xenobiotics).
  • pGP is almost ubiquitous in the human body, as it is expressed in the lower gastrointestinal tract, in organs such as the liver, pancreas, small and large intestines, jejunum, colon, proximal convoluted tubules of the kidney, endothelial cells of the capillaries constituting the blood-brain-barrier, lungs, spleen, skeletal muscles, and the heart (Thiebaut et al, 1987). With this broad distribution, pGP is considered one of the most effective lines of defense against xenobiotics.
  • pGP is not the only protein in the body with this type of transport function; other proteins belonging to the class of ABC transporters, for example, are also involved, directly or indirectly, in mediating the efflux of xenobiotics from the cytoplasm. Such molecules, along with pGP, are often recognized as the cause of multidrug resistance (MDR). Even though these transporters share many structural features and can recognize similar substrates, each member of the family shows a distinct preference for some particular classes of molecules (Sharom, 2008).
  • pGP shows a preferential transport of amphipathic compounds that are positively charged at physiological pH; other transporters, such as MRPl or ABCG2, are less specific and show a preference towards cationic, hydrophilic compounds, usually in the form of conjugates (Cole et al, 1994; Ishikawa et al, 2005; Staud and Pavek, 2005).
  • Inhibition or modulation of pGP activity has therefore long been recognized as a means to modulate drug activity and in particular to enhance the activity of chemotherapeutics towards pGP-overexpressing tumors.
  • pGP inhibition or modulation would improve the efficiency of therapeutics for the central nervous system or the cardiovascular system, and of antimicrobials that are known substrates for pGP (Hunter and Hirst, 1997; Schinkel, 1999).
  • pGP inhibitors were initially identified among existing drugs that were found to be substrates for pGP. These substrates are pharmacological agents with a wide array of indications: from the immunosuppressant cyclosporin, to the chemotherapeutic vincristine, from the protease inhibitors lopinavir and ritonavir, to the antifungal ketoconazole. Although these compounds show a high affinity to pGP, their to xico logical profile at pGP-inhibitory concentrations caused them to fail in clinical trials (Dantzig et al, 2003). Moreover, most of these compounds are also substrates for cytochrome P450 (CytP450), which may lead to drug-drug interactions (Guengerich, 2008, Morrissey et al, 2012; Zhang and Benet, 2001).
  • CytP450 cytochrome P450
  • a second generation of pGP inhibitors was developed in the attempt to overcome the drawbacks of the first generation.
  • Parent drugs underwent small chemical modifications.
  • Dexverapamil and the cyclosporin-analogue valspodar (PSC-833) are potent pGP inhibitors, but suffer from low affinity to the protein, therefore requiring a large therapeutic dose that inevitably elicits side effects.
  • All the second-generation inhibitors failed in clinical trials, due to high toxicity, undesired pharmacokinetics, and again high drug-to-drug interaction via the CytP450 pathway (Darby et al, 2011; Thomas and Coley, 2003).
  • Reversin 121 which is Boc-Asp(Obzl)-Lys(Z)-OtBu, a fully protected dipeptide that has no accessible basic moieties and no charges at physiological conditions, has shown high potency and low toxicity in vitro.
  • Reversin 121 which is Boc-Asp(Obzl)-Lys(Z)-OtBu
  • a fully protected dipeptide that has no accessible basic moieties and no charges at physiological conditions has shown high potency and low toxicity in vitro.
  • Sold as a "for laboratory use only" peptide chemosensitizer and inhibitor of pGP these compounds never entered clinical trials mainly because of their very limited solubility in water (Arnaud et al, 2010).
  • the lack of solubility of Reversin 121 in water is strongly detrimental to its practical in vivo application.
  • Kendarimide A a complex, heavily modified peptide isolated from the marine sponge of Haliclona sp. Its structure is not fully resolved, though it appears to be a highly N-methylated, linear peptide, comprising an intramolecular C-terminal cysteinyl-cysteine 8-membered ring (Aoki et al, 2004; Kotoku et al, 2005). There is no evidence of any follow up to the original study.
  • concentrations required to act as inhibitors of pGP cause adverse effects and drug-to-drug interactions, especially via the interaction with the CytP450 pathway, limiting their use in combination therapy.
  • the ideal pGP inhibitor should preferably not have an activity as a drug on its own. This eliminates all the FDA-approved drugs with pGP-inhibitory activity as possible candidates. Furthermore, the molecule should be small, easy to synthesize by robust procedures, non-toxic, not metabolized by metabolizing enzymes interfering with the activity of the drug for which export by pGP is to be inhibited, and compatible with standard pharmacological routes of application and with formulation protocols. The present invention provides a solution to these problems.
  • Human lactoferrin is a 77 kDa iron-binding glycoprotein of 692 amino acids that constitutes 15% of the amount of protein contained in human mother milk and can also be found in low concentrations in blood plasma (Nemet and Simonovits, Haematologia (Budap.) 18, 3-121985).
  • the bovine homologue (bLF) consists of 688 amino acids and shares 68% amino acid identity with hLF (Crichton, Adv. Protein Chem. 40, 281-363, 1990). However, only 0.5-1% of bovine milk protein is bLF.
  • Lactoferrin (LF) proteins also act as transcription factors (He and Furmanski, Nature 373, 721-724, 1995) and have an impact on immune regulation by inducing the secretion of interleukins (Sorimachi et al, Biochem. Mol. Biol. Int. 43, 79-87, 1997; Vogel et al, 2002).
  • Efflux pumps are surface proteins that can prevent antimicrobial drugs from accumulating in a bacterial cell by identifying and pumping the drugs out of the cell. They are not limited to bacterial cells, but also operate in eukaryotic cells: in eukaryotic cells, efflux pumps can e.g. prevent other drugs from accumulating in diseased cells in a subject by pumping those drugs out of the cell. This efflux of drugs prevents the drugs from achieving therapeutically effective concentrations inside cells. Inhibition of efflux activity would allow drugs to reach an effective concentration inside cells, and would thus potentiate the drug's activity. Various otherwise perfectly suitable drug candidates are not viable for clinical use due to their efflux, caused by efflux pumps. Strategies that administer drugs together with fragments of said drugs have been reported, where specific fragments can competitively inhibit an efflux pump to improve the effect of their corresponding drug (Compton et al, ACS Infect. Dis., 2015, 1 (1), pp 53-58)
  • pGP in its capacity as an efflux pump is present on the wall of the intestinal tract and inhibits the absorption of orally administered drugs.
  • an anticancer agent When orally administered, its absorption and thus its bioavailability is significantly inhibited by the action of pGP (Schinkel, et al, Cell 11, 491-502, 1994).
  • expression of pGP in cancer cells counteracts the activity of anticancer drugs leading to multi-drug resistant cancer cells.
  • a pGP inhibitor when administered in combination with an anticancer agent, it may be possible to facilitate the treatment of a malignant tumor by way of allowing the agent to accumulate in multi-drug resistant cancer cells, due to the inhibitor's activity blocking the activity of pGP as an efflux pump.
  • An aspect of this invention is a new approach to suppressing drug efflux where such efflux counteracts the accumulation of a drug to therapeutic doses, including newly developed drugs. Therefore, there is a need in drug treatment for methods that prevent a drug from being exported by efflux pumps.
  • pGP inhibitors for example, verapamil (a calcium channel inhibitor) and cyclosporin A (an immunosuppressive agent) are known to be effective in reversing the multi-drug- resistance of cancer cells against anticancer agents.
  • verapamil a calcium channel inhibitor
  • cyclosporin A an immunosuppressive agent
  • these compounds exhibit low binding affinities to pGP and as described above, the administration thereof in high dosage may pose a high risk of toxicity.
  • VX-710 a compound that shows pGP- inhibitory activity at a ⁇ concentrations.
  • VX-710 also inhibits the activity of CytP450.
  • VX-710 inhibits the CytP450-mediated metabolism of these drugs, leading to an undesirable increase of the cytotoxic agent in the serum and over-exposure of the patient to the cytotoxic agent.
  • the invention provides for compounds for use in the treatment, delay, prevention, cure, or stabilization of a disorder of a subject in need thereof, comprising or existing of tripeptides of the general structure XAB, wherein A and B represent basic amino acids. A and B can either be different or identical basic amino acids.
  • tripeptides act as substrates for pGP and can therefore competitively inhibit the export of drugs from the cell. These peptides show this activity when added to cells, and even higher such activity when import into the cytoplasm is enhanced, which can either occur by conjugation to a cell-penetrating peptide or by formulation into a carrier such as liposomes or such as (albumin) nanoparticles.
  • the invention relates to compounds as defined above, and their pharmaceutically acceptable salts.
  • the invention relates to compositions that comprise such compounds. These compositions can comprise further excipients.
  • a fourth aspect relates to the use of the compounds or compositions described above.
  • the invention relates to a method for inhibiting pGP in cells, said method comprising contacting the cells with a compound or composition according to the invention.
  • the invention relates to a method of treatment of a disorder, comprising administration of a compound or composition according to the invention to a subject.
  • the invention relates to combination therapy involving the compound or composition according to the invention and further therapeutic compounds. Combination therapy is beneficial and can be synergistic because the pGP-inhibiting effect of compounds or compositions according to the invention can potentiate the effect of further pharmaceutical compounds.
  • the invention provides for a compound comprising or consisting of a tripeptide represented by the sequence XAB, wherein X, A, and B are amino acids, wherein X can be any amino acid and A and B are basic amino acids, for use in the treatment, delay, prevention, cure or stabilization of a disorder of a subject in need thereof, comprising administration to the subject an effective dose of the compound, wherein the compound inhibits p-glycoprotein in its ability to export substances from a cell.
  • Said compound is herein referred to as a compound according to the invention.
  • the compound according to the invention is not conjugated to a drug, preferably not conjugated to a drug selected from the group consisting of Paclitaxel, Methotrexate and Doxirubicin, more preferably the compound according to the invention is not Paclitaxel conjugated to octaarginine or to nonaarginine; Doxirubicin conjugated to penetratin, pegelin, a tat or Tat cell penetrating peptide or a Vectocell peptide; or Methotrexate conjugated to a phage display identified cell penetrating peptide (Vargas, J.R., Mol Pharm. 11, 2553-2565, 2014).
  • a tripeptide is a molecule that comprises three amino acid residues, said three residues forming a single chain.
  • the use of the term peptide or tripeptide should be so construed that next to otherwise featureless tripeptides where each residue is a naturally occurring proteinogenic amino acid linked to its neighbor through a backbone amide bond, also peptides comprising non-natural amino acids, peptidomimetics, unconventional linkages, and many common variations are encompassed.
  • Peptides can comprise amino acids of any chirality, such as L-amino acids or D-amino acids, or mixtures thereof.
  • amino acid' as used in this invention should be interpreted as any moiety that can constitute a residue in a peptide as defined above.
  • an amino acid is a molecular acid, preferably featuring a carboxylic acid, said amino acid featuring an amine at the alpha-carbon next to the carboxylic acid.
  • the amine can also be more distant from the carboxylic acid.
  • Naturally occurring amino acids are also called natural amino acids. Natural amino acids are often proteinogenic, which means that they are used by organisms in the biosynthesis of proteins. In some cases, natural amino acids can also be non-proteinogenic. Natural amino acids are those amino acids that can be found in nature, without further limiting their role or function. As known to a person skilled in the art, amino acids are often characterized by the nature of their side chains. Amino acids that are considered to be basic amino acids are lysine, arginine, and histidine. Amino acids that are considered to be acidic amino acids are aspartic acid, glutamic acid, and tyrosine.
  • Amino acids that are considered to be polar uncharged amino acids are serine, threonine, cysteine, asparagine, and glutamine.
  • Amino acids that are considered to be hydrophobic amino acids are alanine, valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, proline, and tryptophan.
  • Proline is considered to be a conformationally restrained amino acid.
  • Glycine is achiral yet can be part of both D-peptides and L-peptides.
  • tripeptides can be comprised in larger peptides, or in larger molecules.
  • Peptides are understood to possibly comprise capping groups such as terminal amides, acetamides, methyl esters, other terminating esters, or other terminal moieties that are known to a person skilled in the art. Peptides are further understood to possibly feature protecting groups such as t-butyl carbamate, 9-fluorenylmethyl carbamate, benzyl carbamate, benzyl ester, t-butyl ester, methyl ester, or other protecting groups known in the art.
  • the term “treating” preferably means that there is a detectable change in a parameter associated with a disorder in a subject, which can be an improvement in a parameter of the subject itself, or a deterioration of a parameter associated with a parasite, infectious organism, or microbe or other possible factor.
  • the term “delaying” preferably means that a parameter associated with a disorder in a subject is only at a level similar to such a level in an untreated subject after at least 1, 2, 3, 6, 12, 18, 24, 30, 36, 48, 60 or more months.
  • the term "preventing” preferably means that during at least one, two, three, four, five, or more years no parameters associated with a disorder are found to be at levels corresponding to a disorder, meaning the disorder is not or not yet detected.
  • the term “curing” preferably means that there is a change in parameters associated with a disorder in a subject to such an extent that said disorder can no longer be detected.
  • the term “stabilizing” may mean that a parameter associated with a disorder in a subject is unchanged after at least 1, 2, 3, 6, 12, 18, 24, 30, 36, 48, 60 or more months. Therefore, in the context of the invention, preventing, treating, curing, stabilizing and/or delaying a condition may mean that:
  • a symptom is preferably said to have been improved when a parameter associated with said symptom has changed at least 1%, 5%, 10%, 15%, 20%>, 25%, 30%, 35%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%), or more, said change being towards parameter levels found in healthy subjects, or in subjects not in need of treatment. If a parameter has changed 100%, and the change is a decrease, this may mean that the parameter can no longer be detected.
  • a disorder can be any type of disorder with which pGP activity is associated and/or in which it might hinder treatment. As described above, this might be through unwanted export of beneficial drugs from a subject's cells, or through unwanted export of antimicrobial or antibiotic drugs from a microbe or similar subject.
  • a preferred disorder is thus an infection by an organism that could be treated were it not for pGP activity in that organism.
  • a preferred disorder is tuberculosis.
  • a preferred disorder is cancer.
  • a compound comprising a tripeptide represented by the sequence XAB, wherein X, A, and B are amino acids, wherein X can be any amino acid and A and B are basic amino acids, for use in the treatment, delay, prevention, cure or stabilization of a cancer of a subject in need thereof, comprising administration to the subject an effective dose of the compound, wherein the compound inhibits p- glycoprotein in its ability to export substances from a cell.
  • cancers include a cancer of epithelial origin or neuronal origin or a carcinoma or a solid tumor or a sarcoma or a liquid tumor such a leukemia or a lymphoma.
  • Cancer cells may be from the bladder; brain; breast; colon; esophagus; gastrointestine; head; kidney; liver; lung; nasopharynx; neck; ovary; prostate; skin; stomach; testis; tongue; neuron or uterus.
  • the cancer may specifically be of the following histological type, though it is not limited to these: neoplasm; malignant; carcinoma; carcinoma undifferentiated; giant and spindle cell carcinoma; small cell cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma; malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma; familial polyposis coli; solid carcinoma; carcinoid tumor; malignant; branchiolo-alveolar carcinoma; papillary carcinoma; squamous cell carcinoma; basal adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic a
  • a leukemia includes any of: Acute lymphoblastic leukemia (ALL) such as precursor B acute lymphoblastic leukemia, precursor T acute lymphoblastic leukemia, Burkitt's leukemia, and acute biphenotypic leukemia, Chronic lymphocytic leukemia (CLL) such as B-cell prolymphocytic leukemia, a more aggressive disease, Acute myelogenous leukemia (AML) such as acute promyelocyte leukemia, acute myeloblasts leukemia, and acute megakaryoblastic leukemia, Chronic myelogenous leukemia (CML) such as chronic monocytic leukemia, Hairy cell leukemia (HCL), Tcell prolymphocyte leukemia (T-PLL), Large granular lymphocytic leukemia and Adult T- cell leukemia.
  • ALL Acute lymphoblastic leukemia
  • CLL Chronic lymphocytic leukemia
  • AML acute myelogenous leuk
  • a Lymphoma includes any of: Small lymphocytic lymphoma, Lymphoplasmacytic lymphoma (such as Waldenstrom macroglobulinemia), Splenic marginal zone lymphoma, Plasma cell myeloma, Plasmacytoma, Extranodal marginal zone B cell lymphoma (MALT lymphoma), Nodal marginal zone B cell lymphoma (NMZL), Follicular lymphoma, Mantle cell lymphoma Diffuse large B cell lymphoma, Mediastinal (thymic) large B cell lymphoma, Intravascular large B cell lymphoma, Primary effusion lymphoma, Burkitt lymphoma/leukemia, T cell prolymphocyte leukemia, T cell large granular lymphocytic leukemia, Aggressive NK cell leukemia, Adult T cell leukemia/lymphoma, Extranodal NK/T cell lymphoma - nasal type, Enteropathy-type T cell lymphom
  • cancers that is known to feature upregulated pGP activity, or where drug options are limited due to pGP activity, is encompassed within the scope of the invention.
  • Such cancers are in particular ovarian carcinoma and breast cancer, but high expression of pGP is also observed in hepatic carcinomas and some forms of blood cancers.
  • the treatment of a cancer may also be the inhibition of tumor cell proliferation, the induction or increased induction of tumor cell death, the prevention or delay of the occurrence of metastases, the prevention or delay of tumor cell migration, an inhibition or prevention or delay of the increase of a tumor weight or growth, and/or a prolongation of patient survival of at least one month, several months or more (compared to those not treated or treated with a control or compared with the subject at the onset of the treatment) and/or improvement of the quality of life and observed pain relief.
  • a patient may survive and/or may be considered as being disease free. Alternatively, the disease or condition may have been cured or delayed.
  • an improvement of quality of life and observed pain relief may mean that a patient may need less pain relief drugs than at the onset of the treatment. Alternatively or in combination with the consumption of less pain relief drugs, a patient may be less constipated than at the onset of the treatment. "Less” in this context may mean 5% less, 10% less, 20% less, 30% less, 40% less, 50% less, 60% less, 70% less, 80%) less, 90%) less, or 100% less. In this latter case a patient may no longer need any pain relief drug.
  • This improvement of quality of life and observed pain relief may be seen, detected or assessed after at least one week, two weeks, three weeks, four weeks, one month, two months, three months, four months, five months, six months or more of treatment in a patient and compared to the quality of life and observed pain relief at the onset of the treatment of said patient.
  • inhibition of the proliferation of tumor cells is preferably at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or more.
  • Proliferation of cells may be assessed using known techniques, such as FACS or resazurin assays, for example as described in the examples, or by MRI, PET, SPECT, or CT, or by otherwise determining changes in tumor volume or metabolic activity.
  • the proliferation and the status of tumor cells may be assessed through biopsies and (immuno-)histological characterization of the tumor and its surrounding tissue.
  • An induction of tumor cell death may be at least 1%, 5%, 10%>, 15%, 20%>, 25%, or 25 more.
  • Tumor growth may be inhibited at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 55%), 60%), 65%), 70%) or 75%, or more.
  • Tumor cell death may be assessed using techniques known to the skilled person. Tumor cell death may be assessed using MRI, PET, SPECT, or CT, or by otherwise determining changes in tumor volume or metabolic activity. The death or decrease in activity of tumor cells may be assessed through biopsies and (immuno-)histological characterization of the tumor and its surrounding tissue. In certain embodiments, tumor weight increase or tumor growth may be inhibited at least 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70% or 75%, or more. Tumor weight or tumor growth may be assessed using techniques known to the skilled person.
  • the detection of tumor growth or the detection of the proliferation of tumor cells may be assessed in vivo by measuring changes in glucose utilization by positron emission tomography with the glucose analogue 2-[18F]-fluor-2-deoxy-D-glucose (FDG-PET) or [18F]-'3-fluoro-'3- deoxy-L-thymidine PET.
  • FDG-PET glucose analogue 2-[18F]-fluor-2-deoxy-D-glucose
  • An ex vivo alternative may be staining of a tumor biopsy with Ki67.
  • a subject can be any living entity.
  • a subject is a human being.
  • a subject may be a microorganism or a microbe or a parasite.
  • subjects may be animals, plants, or fungi of any kind.
  • a subject may be a single cell, or a culture of cells, either cultured in vitro, or obtained from a subject and maintained ex vivo.
  • Subjects are in need of treatment when parameters associated with a disorder can be detected, or when such parameters are expected to become detectable, or when such parameters are feared to become detectable.
  • Administration of a compound or composition according to the invention can be achieved by any method known in the art, as further defined later in this text.
  • an effective dose of a compound or composition is a dose that can assert a desired effect, such as improving a symptom of a disorder, or changing a parameter associated with a disorder.
  • inhibition of p-glycoprotein comprises a detectable reduction in the activity of pGP as an efflux pump as measurable by an assay, or as concluded from an experiment.
  • an assay can be one where accumulation of fluorescent products, or the absence thereof, is determined, for example as described in the examples. It can also comprise a detectable reduction in the ATPase activity of pGP.
  • Reduction preferably means that activity has been reduced by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% as compared to activity in an untreated reference sample, assayed under identical conditions where a reduction of 100% may mean that no activity can be detected.
  • the ability of pGP to export substances from a cell should be interpreted as its ability to neutralize substances, or to remove them from bioavailability, where substances should be read as molecules, complexes of multiple molecules, oligomers, polymers, polypeptides, proteins, or particles.
  • Neutralization should be construed as the removal of a substance from its available status. Preferably, this happens through transport, which is preferably from inside a cell to outside a cell, which is generally depicted as efflux or export.
  • pGP when pGP is said to export a substance from a cell, it is to be understood that such export can be export of a substance from the cell's lumen including but not being restricted to the cytoplasm, from the plasma membrane lipid bilayer, or from any other compartment of the cell.
  • Compounds as described in this aspect of the invention may be the compounds as such or may be a pharmaceutically acceptable salts of such a compound or of a related compound according to the invention.
  • B and/or X are preferably terminal amino acids.
  • a terminal amino acid is the last or the first amino acid of a sequence of amino acids, so that a terminal amino acid only has either a preceding or a subsequent amino acid, not both.
  • a terminal amino acid is not connected to any other moiety, except to the sequence of which it is a terminal amino acid, and possibly except to any capping moieties or protecting groups such as known in the art and/or described above.
  • X is a terminal amino acid.
  • B is a terminal amino acid.
  • X and B are both terminal amino acids.
  • At least one of X, A, and B is a natural amino acid, preferably an L-amino acid.
  • at least two of X, A, and B are natural amino acids, preferably L-amino acids.
  • each of X, A, and B are natural amino acids, preferably L-amino acids.
  • each of X, A, and B are natural L-amino acids.
  • either A or B are selected from the group consisting of Arginine, Lysine and Histidine.
  • a and B are each independently selected from the group consisting of Arginine, Lysine and Histidine.
  • a and/or B are each independently selected from Arginine or Lysine.
  • X is selected from the group consisting of Asparagine, Tryptophan, and any amino acid with a side chain that consists of only carbon and hydrogen atoms.
  • X is selected from the group consisting of Asparagine, Tryptophan, Alanine, Valine, Isoleucine, Leucine, and Phenylalanine.
  • X is selected from the group consisting of Alanine, Isoleucine, Asparagine, and Tryptophan.
  • X is selected from the group consisting of Alanine, Isoleucine, Asparagine, and Tryptophan, and A and B are each independently selected from the group consisting of Arginine, Lysine, and Histidine.
  • X is selected from the group consisting of Alanine, Isoleucine, Asparagine, and Tryptophan, and A and B are each independently selected from Arginine or Lysine.
  • the compound preferably consists of a tripeptide represented by the sequence XAB.
  • XAB is IK , being Ile-Lys-Arg.
  • XAB is AKR, being Ala-Lys-Arg.
  • XAB is WKK, being Trp-Lys-Lys.
  • XAB is NRR, being Asn-Arg-Arg.
  • tripeptides according to the invention are a preferred embodiment.
  • Compounds according to the invention comprising tripeptides are advantageous over previously existing pGP-inhibitor candidates due to their excellent solubility in water at physiological conditions.
  • Physiological conditions are known to a person skilled in the art, and comprise atmospheric pressure, pH-values between 6 and 8, a temperature ranging from room temperature to about 37° C (from about 20° C to about 40° C), and a suitable concentration of buffer salts or other components.
  • compounds according to the invention can easily be produced, e.g. synthetically in well under ten reaction steps using standard techniques, reactants, and reagents.
  • Another advantage of compounds according to the invention is that in some embodiments the compounds can independently enter cells to more effectively assert their therapeutic effect.
  • Previously existing pGP-inhibitor candidates were often found to lack solubility or to otherwise lack bioavailability. This problem is solved by the invention.
  • any of the compounds as defined above further comprises a peptide, a drug, and/or a label.
  • the compound according to the invention is not conjugated to a drug selected from the group consisting of Paclitaxel, Methotrexate and Doxirubicin, more preferably the compound according to the invention is not Paclitaxel conjugated to octaarginine or to nonaarginine; Doxirubicin conjugated to penetratin, pegelin, a tat or Tat cell penetrating peptide or a Vectocell peptide; Methotrexate conjugated to a phage display identified cell penetrating peptide (Vargas, J.R., Mol Pharm. 11, 2553-2565, 2014).
  • XAB is comprised in a peptide.
  • XAB is at the terminus of a peptide.
  • the compound is the peptide represented by KCFQWQRNMRKVRGPPVSCIKR (SEQ ID NO: 2), which is referred to as hLF.
  • the compound is the peptide represented by RQIKIWFQNRRMKWKK (SEQ ID NO: 5), which may be referred to as penetratin or antennapedia.
  • penetratin or antennapedia can be used with or without various end group modifications, such as for example and not limited to: H-KCFQWQRNMRKVRGPPVSCIKR-OH, or
  • a compound according to the invention comprises both a first peptide and the tripeptide XAB in such a manner that XAB is not comprised in the first peptide, such as in R9-ahx-IKR (SEQ ID NO: 17), which is a preferred embodiment.
  • ahx represents 6-aminohexanoic acid, which is also known as aminocaproic acid, which in turn is abbreviated as Acp.
  • Ahx is considered to be a linker moiety that links two further moieties together.
  • linkers can be used, such as, but not limited to, beta-alanine (also known as beta-aminopropionic acid, bAla), 4-Aminobutyric acid (also known as piperidinic acid, 4Abu), 3-Aminoisobutyric acid (bAib), or other linking moieties known in the art.
  • beta-alanine also known as beta-aminopropionic acid, bAla
  • 4-Aminobutyric acid also known as piperidinic acid, 4Abu
  • 3-Aminoisobutyric acid bAib
  • tat is a peptide known to be a cell penetrating peptide that comprises the amino acid sequence RKKRRQRRR (SEQ ID NO: 6), and wherein Tat is a longer version of tat, comprising the amino acid sequence GRK R QRRRPQ (SEQ ID NO: 7).
  • the XAB moiety can also be linked to a peptide through grafting of XAB to the side chain of a residue, resulting for example in amino acid residues such as -Lys(XAB-OH)-.
  • Examples of such a preferred embodiment would be H- RRRRRRRR (IKR)-OH, or H-K(IKR)RRRRRR-OH.
  • a further preferred further embodiment is a fusion protein comprising a molecule according to the invention.
  • the compound according to the invention further comprises a label.
  • a label is understood to be any moiety that facilitates detection using a method for detection, whereby such a label is a fluorophore, a chromophore, a radioactive tracer, a specific isotope, a diagnostic marker, or a hapten, wherein a hapten is preferably biotin.
  • the compound is radioactively labeled, preferably by having incorporated a radioactively labeled amino acid, whereby more preferably the radioactively labeled amino acid is a tritium-labelled amino acid.
  • a label is a diagnostic marker, it may be a fluorogenic substrate to detect the activity of a pathologically relevant protease, for example a caspase involved in the initiation and execution of apoptosis in a cell.
  • labeled compounds according to the invention are fluorescein-fiLF, fluorescein-mLF (where mLF represents a peptide known to be a cell penetrating peptide derived from murine lactoferrin), fluorescein-penetratin, fluorescein- ahx-IKR, fluorescein-IKR, fluorescein-Rs-ahx-IKR.
  • the compound according to the invention further comprises a drug or a drug candidate.
  • a drug can be a small molecule, a peptide, a depsipeptide, an acyldepsipeptide, an antibiotic, an antimicrobiotic, a polypeptide, a protein, a protein fragment, a nucleic acid, a nucleic acid analogue, or parts thereof, a chemotherapeutic, a decoy molecule, or any other entity or combination thereof.
  • a nucleic acid can be selected from the group comprising DNA molecules, RNA molecules, PNA molecules, oligonucleotides, siRNA molecules, antisense molecules, ribozymes, aptamers, and aptmers.
  • a drug is understood to be any entity that can assert a therapeutic effect, which can also be for vaccination.
  • Non-limiting examples of preferred drugs are daunorubicin and doxorubicin.
  • a compound comprising or consisting of a tripeptide represented by the sequence XAB, wherein X, A, and B are amino acids, wherein X can be any amino acid and A and B are basic amino acids, for use in increasing the residence time of a drug inside a cell.
  • XAB tripeptide represented by the sequence XAB
  • X, A, and B are amino acids
  • X can be any amino acid
  • a and B are basic amino acids
  • a drug preferably has an increased residence time in a cell when more of the drug can be detected inside a cell after a given amount of time when a compound according to the invention has also been administered, as compared to when only the drug has been administered.
  • preferred amounts of time after which to determine residency are 30 minutes, one hour, two hours, three hours, four hours, or five hours, preferably four hours.
  • a compound is provided that is defined as any of the compounds described above, which includes compounds named above.
  • Such compounds comprise a tripeptide represented by the sequence XAB, wherein X, A, and B are amino acids, wherein X can be any amino acid and A and B are basic amino acids.
  • X and/or B can be terminal amino acids.
  • X and/or A and/or B can be natural amino acids, preferably L-amino acids.
  • a and B can each be independently selected from the group consisting of Arginine, Lysine and Histidine, preferably selected from Arginine and Lysine.
  • X can be selected from the group consisting of Asparagine, Tryptophan, or any amino acid with a side chain that consists of only carbon and hydrogen atoms, preferably X is selected from the group consisting of Alanine, Isoleucine, Asparagine, and Tryptophan.
  • X is selected from the group consisting of Alanine, Isoleucine, Asparagine, or Tryptophan and A and B are each independently selected from the group consisting of Arginine, Lysine and Histidine, preferably selected from Arginine and Lysine.
  • the compound consists of a tripeptide represented by the sequence XAB, wherein XAB preferably is IK or AKR, more preferably IKR.
  • the compound can further comprise a peptide, a drug and/or a label as specified above.
  • Compounds as described in this aspect of the invention may be the compounds as such or may be a pharmaceutically acceptable salt of such a compound or of a related compound according to the invention.
  • a composition comprising a compound according to the invention is provided.
  • the composition further comprises an excipient, preferably a pharmaceutically acceptable excipient.
  • compositions that comprise a compound according to the invention, a pharmaceutically acceptable excipient, and further comprises a therapeutic compound.
  • compositions that comprise liposome formulations as an excipient are based on DPPC or on DOPE or on combinations thereof.
  • a preferred formulation is DPPC/DOPE/CHEMS/Cholesterol 4:2:2: 1.
  • a more preferred formulation is DPPC/Cholesterol 2: 1.
  • Liposomes may further feature acylated peptides, other acylated functional molecules, and may carry further cargo molecules, in particular liposomes may feature a shell of poly ethylenegly cols to enhance circulation time in a subject.
  • compositions that comprise nanoparticle formulations as an excipient are albumin nanoparticle formulations.
  • Albumins are globular proteins that are easy to purify, biodegradable, and that have low toxicity and little potential to trigger immune responses.
  • Albumin nanoparticles comprise crosslinked albumin proteins.
  • a preferred albumin is human serum albumin, more preferably recombinant serum albumin, because this further decreases the chance of an undesired immune response.
  • the composition is for use in the treatment, delay, prevention, cure or stabilization of a disorder, preferably cancer, of a subject in need thereof, said use comprising administration to the subject of an effective dose of the composition, wherein the composition inhibits p-glycoprotein in its ability to export compounds from a cell.
  • the composition is for use in increasing the residence time of a drug in a cell.
  • the use is provided of either a compound according to a previous aspect of the invention, or of a composition according to a previous aspect of the invention.
  • Said use is for the treatment, delay, prevention, cure or stabilization of a disorder of a subject in need thereof, and comprises administration to the subject of an effective dose of a compound according to the invention or of a composition according to the invention, wherein the compound or composition inhibits p-glycoprotein in its ability to export substances from a cell.
  • the use is provided of either a compound according to the invention, or of a composition according to the invention, for the treatment, delay, prevention, cure or stabilization of a cancer of a subject in need thereof, and comprises administration to the subject of an effective dose of a compound according to the invention or of a composition according to the invention, wherein the compound or composition inhibits p-glycoprotein in its ability to export substances from a cell.
  • the use is provided of either a compound according to the invention, or of a composition according to the invention, for increasing the residence time of a drug in a cell.
  • Terms, features and definitions are preferably as provided above.
  • a fifth aspect of the invention provides a method for inhibiting p-glycoprotein in its ability to export substances from a cell, said method comprising contacting the cell with a compound according to the invention, or with a composition according to the invention.
  • contacting a cell with a compound or a composition can comprise adding such a compound or composition to a medium in which a cell is cultured.
  • Contacting a cell with a compound or a composition can also comprise adding such a compound or composition to a medium, buffer, or solution in which a cell is suspended, or which covers a cell.
  • Other preferred methods of contacting a cell comprise injecting a cell with a compound or composition, or exposing a cell to a material comprising a compound or composition according to the invention.
  • the method is an in vitro method. In a further embodiment of this aspect, the method is an ex vivo method. In a further embodiment of this aspect, the method is an in vivo method. In a preferred embodiment of this aspect, the method is an in vitro or an ex vivo method.
  • the cell can be a cell from a sample obtained from a subject.
  • a sample can be a sample that has been previously obtained from a subject.
  • samples can have been previously obtained from a human subject.
  • samples can have been obtained from a non-human subject.
  • obtaining the sample is not part of the method according to the invention.
  • the method is for increasing the residence time of a drug inside a cell.
  • a method of treatment is provided.
  • Said method can be used to treat, delay, prevent, cure or stabilize a disorder of a subject in need thereof, and comprises administration to the subject of an effective dose of either a compound according to the invention, or of a composition according to the invention, wherein the compound or composition inhibits p-glycoprotein in its ability to export substances from a cell.
  • the disorder is a cancer.
  • combination therapy is provided.
  • a compound for use according to the first aspect of the invention is administered together with an effective dose of a further therapeutic compound or composition.
  • a composition for use as defined above is administered together with an effective dose of a further therapeutic compound or composition. It is within embodiments of this aspect that a use as described is combined with administration of an effective dose of another therapeutic compound or composition. It is within embodiments of this aspect that a method of this invention further comprises administration of an effective dose of another therapeutic compound or composition.
  • a compound, composition, use, or method according to this invention is effectuated simultaneously with the administration of said further therapeutic compound or composition, which is referred to as simultaneous administration.
  • the administration of said further therapeutic compound or composition can take place either before or after the use or method according to this invention, which is referred to as separate administration.
  • separate administration can comprise administrations that are separated by a minimal amount of time, or by 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, or more minutes, or by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more hours, or by 1 , 2, 3, 4, 5, or more days, or by a week or by a month or by a longer duration of time.
  • further therapeutic compounds or compositions are preferably compounds or compositions that comprise substrates of pGP. More preferred further therapeutic compounds or compositions are such entities that are limited in their therapeutic effect as a result of pGP-activity, or that have undesirable distribution profiles, metabolic profiles, excretion profiles, or toxicity profiles, as a result of pGP- activity. Combination of such a compound or composition with a compound or composition according to the invention can help overcome, or otherwise ameliorate or obviate these undesirable characteristics.
  • Non-limiting examples of preferred further therapeutic compounds or compositions are, or comprise, Actinomycin, All-trans retinoic acid, Azacitidine, Azathioprine, Bleomycin, Bortezomib, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Etoposide, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imatinib, Irinotecan, Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel (Taxol), Pemetrexed, Teniposide, Tioguanine, Topotecan, Valrubicin, Vinblastine, Vincristine, Vindesine, or Vinorelbine, more
  • a peptide in the context of this invention, can be obtained by isolating it from a natural product.
  • Peptides can be obtained through isolation from a digest of a larger protein.
  • peptides according to the invention are of synthetic origin.
  • a preferred method for peptide synthesis is solid phase peptide synthesis (SPPS), which is well- known to a person skilled in the art. Advantages of obtaining short peptides through SPPS are the ease of synthesis, the low component cost, the speed of synthesis, and the possibility for automation using synthesis robots, synthesizers, semi-automatic synthesizers, or automatic synthesizers. Peptides or peptide analogues according to the invention are therefore more readily accessible than many other molecules.
  • Compounds according to the invention that comprise peptides featuring a XAB motif embedded in an encompassing peptide sequence are especially accessible using this strategy.
  • SPPS strategies known in the art allow both N-terminal and C-terminal modification, such as alkylation, amidation, or labeling.
  • the compounds or compositions according to the invention are preferably delivered to a specific type of cells or tissue or organ comprising such specific type of cells. In a preferred embodiment such specific delivery is mediated through a targeting moiety or a targeting molecule that may be comprised in the molecule or composition according to the invention.
  • compositions and pharmaceutical compositions according to the invention may be manufactured by processes well known in the art; e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes, which may result in liposomal formulations, coacervates, oil- in- water emulsions, nanoparticulate/microparticulate powders, or any other shape or form.
  • Compositions for use in accordance with the invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent on the route of administration chosen.
  • compositions or a pharmaceutical composition according to the invention When a composition or a pharmaceutical composition according to the invention is encapsulated, all components of said composition are preferably encapsulated in the same resulting particle.
  • Coencapsulation of a compound according to the invention with a further therapeutic compound ensures simultaneous delivery and thus mitigates differences in pharmacodynamics properties that might reduce the positive effect of a compound according to the invention on said further therapeutic agent.
  • the compounds according to the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
  • physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
  • penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • Formulations that promote penetration of the epidermis are known in pharmacology, and can find use in the treatment of many skin conditions, such as, but not limited to, psoriasis and fungal infections. Formulations that promote penetration of the epidermis and underlying layers of skin are also known, and can be used to apply compositions of the invention to, for example, underlying muscle or joints.
  • formulation comprising compositions according to the invention that deliver compounds for alleviation of rheumatoid- or osteo-arthritis can be administered by applying a cream, ointment, or gel to the skin overlying the affected joint.
  • Oral and parenteral administration may be used where the compound and/or composition is stable enough to endure the harsh proteolytic environment of the gut.
  • the compound or composition according to the invention can be formulated readily by combining a compound or composition according to the invention with pharmaceutically acceptable carriers well known in the art, or by using a compound or composition according to the invention as a food additive.
  • Such strategies enable the compounds or compositions according to the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated.
  • Preparations or pharmacological preparations for oral use can made with the use of a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
  • fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol
  • cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose
  • disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Additionally, co formulations may be made with uptake enhancers known in the art, or with proteolytic inhibitors known in the art.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, PVP, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solution, and suitable organic solvents or solvent mixtures.
  • Polymethacrylates can be used to provide pH-responsive release profiles so as to pass the stomach.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions which can be adminstered orally include push- fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
  • the compounds or compositions according to the invention may be administered in the form of tablets or lozenges formulated in a conventional manner.
  • the compounds and compositions according to the invention can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethan
  • the compound or composition according to the invention may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. In this way it is also possible to target a particular organ, tissue, tumor site, site of inflammation, etc.
  • Formulations for infection may be presented in unit dosage form, e.g., in ampoules or in multi-dose container, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • compositions or pharmaceutical compositions for parenteral administration include aqueous solutions of the compositions in water soluble form. Additionally, suspensions of the compositions may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compositions to allow for the preparation of highly concentrated solutions. Alternatively, one or more components of the composition may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • compositions may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • compositions according to the invention may also be formulated as a depot preparation.
  • Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compositions may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil), or as part of a solid or semi-solid implant that may or may not be auto- degrading in the body, or ion exchange resins, or one or more components of the composition can be formulated as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • suitable polymeric materials are known to the person skilled in the art and include PLGA and polylactones such as polycaproic acid.
  • compositions or pharmaceutical compositions according to the invention also may comprise suitable solid or gel phase carriers or excipients.
  • suitable solid or gel phase carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • compositions and/or pharmaceutical compositions for use in the invention include compounds and compositions wherein the active ingredients are contained in an amount effective to achieve their intended purposes. More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • the therapeutically effective amount or dose can be estimated initially from cell culture assays.
  • a dose can be formulated in animal models to achieve a circulating concentration range that includes the IC50 as determined in cell culture (where inhibitor molecules are concerned). Such information can be used to more accurately determine useful doses in humans.
  • Toxicity and therapeutic efficacy of a compound or composition according to the invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50 % of the population) and the ED50 (the dose therapeutically effective in 50 % of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio between LD50 and ED50.
  • Compounds or compositions exhibiting high therapeutic indices are preferred.
  • the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for human use. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al, 1975, in "The Pharmacological Basis of Therapeutics" Ch. 1 p. 1).
  • the amount of compound or composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
  • a pharmaceutical composition that comprises a compound or a composition according to the invention in combination with a further therapeutic compound can be supplied such that the compound and one or more of the composition components, and the further therapeutic compound are in the same container, either in solution, in suspension, or in powder form.
  • the compound or composition according to the invention can also be provided separately from one or more of the further molecules, and can be mixed with one or more of the further molecules prior to administration.
  • Various packaging options are possible and known to the ones skilled in the art, depending, among others, on the route and mechanism of administration.
  • compositions may, if desired, be presented in a pack having more than one chamber, and in which a barrier can be ruptured, ripped, or melted to provide mixing of the compound or composition according to the invention with the further therapeutic compound.
  • two separately provided elements can be mixed in a separate container, optionally with the addition to one or more other carriers, solutions, etc.
  • One or more unit dosage forms containing the further therapeutic compound can be provided in a pack.
  • the pack or dispenser device may be accompanied by instructions for administration.
  • Compositions comprising a compound according to the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Suitable conditions indicated on the label may include any disease which may be treated or prevented or diagnosed using the compositions according to the invention.
  • the invention is ideally suited to cancer therapy or chemotherapy.
  • Compounds according to the invention can be compounds that are also cell penetrating peptides.
  • the compounds according to the invention are specifically not for use as a cell penetrating peptide, and are as such specifically not used as cell penetrating peptides.
  • the compounds according to the invention are for example not used to promote entry into a cell of the compound itself, or of further compounds, or to induce ceramide formation in a cell.
  • the invention allows for the prevention of side effects through its use of low doses.
  • pGP-inhibitors known in the prior art are often only effective at doses that incur severe side effects.
  • the invention allows for dosage regimes that involve an intake schedule featuring intake moments that occur multiple times a day, daily, once every four days, weekly, twice a week, preferably six, five, four, or three times a week, more preferably even less often, thus relieving the burden on the patient.
  • an improvement of a parameter may be measured immediately after a single treatment, or after an hour, two hours, four hours, twelve hours, or after one day, two days, four days, or after at least one week, one month, six months of treatment or more.
  • a symptom may be any symptom known in the art.
  • a parameter may be the assessment of pGP activity as explained herein, or the proliferation of cancer cells as explained herein. The experience of symptoms by the patient may be assessed by interview or anamnesis, or alternately by known tests that assess condition or fatigue levels as appropriate. When appropriate, a parameter can be considered to be improved or deteriorated on the indication of the subject.
  • Proliferation of cells and/or cell viability may be assessed using known techniques such as FACS techniques or other techniques, including techniques as described in the examples. Proliferation of cells and/or cell viability may also be assessed using other known techniques, such as resazurin assays, for example as described in the examples, or by MRI, PET, SPECT, or CT, or by otherwise determining changes in cell metabolic activity. The proliferation and the status of cells may be assessed through biopsies and (immuno-)histological characterization of the cells and possible surrounding tissue. When FACS is used to assess cell proliferation, a detected reduction in cell numbers can indicate that the compound or composition according to the invention has a therapeutic effect. Enzyme expression and/or activity can be assessed using known techniques.
  • a decrease or increase of a parameter to be assessed means a change of at least 5% of the value corresponding to that parameter. More preferably, a decrease or increase of the value means a change of at least 10%, even more preferably at least 20%, at least 30%, at least 40%, at least 50%, at least 70%, at least 90%, or 100%. In this latter case, it can be the case that there is no longer a detectable value associated with the parameter.
  • the word "about” or “approximately” when used in association with a numerical value preferably means that the value may be the given value (of 10) more or less 0.1%) of the value.
  • a cell can be a cell from a sample obtained from a subject.
  • a sample can be a sample that has been previously obtained from a subject.
  • Such a sample can be obtained from a human subject.
  • Such a sample can be obtained from a non- human subject.
  • FIGURE LEGENDS Figure 1 A first figure.
  • daunorubicin shows a time and dose-dependent cell killing.
  • Cell viability measured by mitochondrial activity on MES1977 cells (resazurin assay) incubated with DNR and hLF (5 ⁇ ) for A) 2 hours, B) 2 hours followed by 24 hours recovery in the absence of drug and peptide, and C) incubated with DNR and peptide for 24 hours.
  • MES1977 cells were incubated for 4 hours with daunorubicin (250 ig/ml), alone or in combination with hLF, D-hLF, R9, D-R9, and Penetratin (5 ⁇ ).
  • daunorubicin 250 ig/ml
  • hLF hLF
  • D-hLF D-hLF
  • R9 D-R9
  • Penetratin 5 ⁇ .
  • B Annexin V positive cells, as measured by flow cytometry.
  • MES1977 cells were incubated for 4 hours with daunorubicin (250 ig/ml), alone or in combination with H-IKR-OH or with H-IKR-NH2 (5 ⁇ ).
  • hLF is a substrate for pGP.
  • MES1977 cells incubated for 1 hour with DNR (250 ig/ml), or fluorescein-labelled analogs of any one of hLF, mLF, R9, or penetratin (2.5 ⁇ ), in the presence or absence of PSC-833 (5 ⁇ ). Ratios of median fluorescein fluorescence intensity obtained by flow cytometry.
  • the C-terminal IKR motif causes inhibitory activity. This activity can be transplanted onto a cell-penetrating peptide which by itself does not act as a pGP inhibitor.
  • MES1977 cells were incubated for 24 hours with DNR (250 ig/ml) and different peptides carrying or lacking the IKR motif (5 ⁇ ).
  • Penetratin does not carry the IKR motif, but carries a WKK and an NRR motif.
  • the C-terminal IKR motif is sufficient to induce cell death and caspase activation.
  • MES1977 cells were incubated for 5 hours with DNR (250 ig/ml) and different peptides carrying or lacking the IKR motif (5 ⁇ ).
  • the IKR motif is a substrate for pGP. This activity can be transferred onto other peptides. Fluorescein- labeled peptides (100 ⁇ ) were incubated with pGP-outside/in vesicles in the presence of either AMP or ATP. pGP can only transport substrates in the presence of ATP; the higher the ratio, the more efficient the transport.
  • doxorubicin The cytotoxic effect of doxorubicin on pGP-expressing cell lines is enhanced by the presence of Rs-ahx-IKR.
  • Cell viability was measured by mitochondrial activity after 24 hours incubation with DOX and Rs-ahx-IKR (5 ⁇ ).
  • the cytotoxic effect of liposomal doxorubicin on pGP-expressing cell lines is enhanced by the presence of IKR.
  • DOX and IKR were co-encapsulated in the same vesicles.
  • Cell viability was measured by mitochondrial activity after 24 hours incubation with DOX and IKR (5 ⁇ ).
  • doxorubicin- loaded nanoparticles on pGP-expressing cell lines is enhanced by the presence of IKR.
  • DOX and IKR were co-loaded in the same albumin nanoparticles.
  • Cell viability was measured by mitochondrial activity after 24 hours incubation with DOX and IKR (5 ⁇ ).
  • the growth inhibition induced by paclitaxel-loaded nanoparticles on pGP-expressing cell lines is enhanced by the presence of IKR.
  • PTX and IKR were co-loaded in the same albumin nanoparticles.
  • Cell viability was measured by mitochondrial activity after 24 hours incubation with PTX and IKR (5 ⁇ ).
  • Doxorubicin accumulates in HL-60/VCR in presence of Rs-Ahx-IKR or IKR.
  • MES1977 cells which are used in the examples, are known in the art and are also referred to as MES-SA 1977 cells, or as MES-SA/Dx5 cells, or as MES 1977 cells.
  • Example 1 hLF potentiates daunorubicin activity.
  • MES 1977 cells were exposed to increasing concentrations of daunorubicin (DNR) in the absence or presence of 5 f M hLF ( Figure 1).
  • DNR daunorubicin
  • Figure 1 Cell viability as determined by the resazurin assay was determined after incubation for A) 2 hours, B) 2 hours followed by 24 hours recovery in the absence of drug and peptide, and C) incubated with DNR and peptide for 24 hours.
  • a resazurin assay measures mitochondrial activity. If cells are exposed to any form of stress, they can temporarily switch off the mitochondria and this results in a false positive reading for cell toxicity. Cells can restore their mitochondrial activity when the stress is removed, i.e. upon removal of DNR. Positive readings after a long recovery (24 hours is considered to be a sufficiently long recovery by a very safe margin) in the absence of DNR will show indubitably that mitochondrial activity is irreversibly compromised, and that cells are thus indeed dead or close to death.
  • Example 2 Potentiation of daunorubicin activity is not a general characteristic of cationic cell-penetrating peptides.
  • the drug-activity-enhancing effect of hLF could hypothetically be attributed to the activity of hLF as a cell-penetrating peptide.
  • neither the highly active CPP nonaarginine, nor its D-amino acid counterpart enhanced daunorubicin toxicity did not observed for the D-analog of hLF in the induction of phosphatidylserine exposure as probed by Annexin V staining, and also the CPP penetratin showed an enhancing effect (Figure 2).
  • the peptide was found to interfere with pGP-mediated export of the drug. To do so, the peptide could either serve as a substrate for pGP and thus compete with the drug for export, or it could interfere with the expression of the transporter on the cell surface, or thirdly, it could disturb pGP functionality without being a substrate.
  • Example 4 For hLF, the terminal IKR motif is responsible for activity.
  • the structural element within hLF responsible for this activity was identified.
  • the C- terminal IKR motive of the hLF was found to act as a pGP substrate.
  • Example 5 Cell-free assessment of IKR activity.
  • the retro tripeptide (RKI) and the chirally inverted tripeptide (D-IKR, which can also be denoted as ikr) were not as efficient in enhancing the efficacy of daunorubicin, consistent with the limited potentiating effect observed for D-hLF.
  • a tripeptide is the shortest possible sequence to show activity, as the dipeptides IK and KR did not significantly potentiate the cytotoxic effect of DNR when in coformulation with DNR ( Figure 10).
  • Tripeptides according to the invention are convenient to handle and are expected to have excellent (bio)adsorption and (bio)distribution parameters, owing to their excellent solubility in water and aqueous buffer solutions.
  • This example provides calculated LogP values that corroborate and quantify the previously obtained data.
  • Solubility is commonly expressed as a partition ratio (LogP), which is the ratio of concentrations of a compound in a mixture of two immiscible phases at equilibrium (here: water and 1-n-octanol).
  • LogP is a measure of the difference in solubility of the compound in question in these two phases. More precisely, LogP expresses the ratio of concentrations of the compound in question in the two phases of water and 1-n-octanol at equilibrium. Therefore, LogP is often seen as a measure of how hydrophilic or hydrophobic a compound can be assumed to be.
  • LogP values can be estimated using computational chemistry (Tetko et al, J. Comput. Aid. Mol. Des., 2005, 19, 453-63.) Table 2 below provides calculated LogP values for various compounds, including the tripeptide IKR. Calculations were performed using VCCLAB, Virtual Computational Chemistry Laboratory, accessible on the internet at www.vcclab.org, 2005. It can be concluded that IKR is exceptionally well-soluble in water. This characteristic of IKR combines well with its previously demonstrated ability to independently enter cells.
  • Liposomal formulations as used in some aspects or embodiments of the invention can be based on DPPC or on DOPE or on combinations thereof.
  • a preferred formulation is DPPC/DOPE/CHEMS/Cholesterol 4:2:2: 1, which was shown to encapsulate approximately 48 ⁇ g of DNR per mg of lipid.
  • a more preferred formulation is DPPC/Cholesterol 2: 1, which was shown to encapsulate approximately 65 ⁇ g DNR per mg of lipid.
  • IKR potentiates doxorubicin activity in pGP-expressing cells.
  • Doxorubicin (DOX) was administered to three different cell lines: to Jurkat cells, to SH- SY5Y cells, and to HL-60/VCR cells. Each of these cell lines expresses pGP. Doxorubicin was administered in a range of concentration from 0 to 100 ⁇ g/ml, in the presence and absence of Rs-ahx-IKR (5 ⁇ ). Cell viability was measured by determining the mitochondrial activity of the cells after 24-hours incubation.
  • DOX was encapsulated into liposomes.
  • a set of DOX- liposomes with and without coencapsulated IKR (initial IKR concentration: 20 ⁇ ) was prepared.
  • the liposomal formulations were administered to Jurkat cells, to SH-S Y5 Y cells, and to HL-60/V CR cells, at equivalent DOX concentrations ranging from 0 to 50 ⁇ g/ml.
  • Cell viability was measured by determining the mitochondrial activity of the cells after 24-hours incubation. Here, too, cell viability decreased in a dose-dependent manner for all cell lines.
  • Albumin-based nanoparticles are an emerging class of drug delivery vehicles that provide a good pharmacological and toxicological alternative to liposomes and polymeric nanoparitcles. They consist of cross-linked albumin proteins instead of from lipids or synthetic polymers. Albumin nanoparticles can be produced with albumins from different sources (bovine, human), obtained by purification from blood or via molecular biology tools such as recombinant expression. The synthesis of albumin nanoparticles is low-cost and convenient. Particle size and drug loading can be tuned by changing synthesis parameters such as pH, concentration of crosslinkers, and annealing times. Albumin nanoparticles sometimes possess more favourable physicochemical properties compared to liposomes. For initial tests as reported here, bovine serum albumin was used; however, future formulations will be based on recombinant human serum albumin, to further decrease chances of inducing undesired immune responses.
  • Doxorubicin was encapsulated into albumin nanoparticles, with a set of albumin nanoparticles also comprising IKR (initial IKR concentration: 20 ⁇ ; expected effective IKR concentration when particles are administered to cells: 5 ⁇ ), and another set only comprising doxorubicin.
  • the formulations were administered to Jurkat cells, to SH- S Y5 Y cells, and to HL-60/V CR cells, at equivalent DOX concentrations ranging from 0 to 50 ⁇ g/ml. Cell viability was measured by determining the mitochondrial activity of the cells after 24-hours incubation.
  • Paclitaxel was administered to Jurkat cells, to SH-SY5Y cells, and to HL-60/VCR cells, in a range of concentration from 1 to 100 nM, in the presence or absence of Rs- ahx-IKR (5 ⁇ ). Cell viability was measured by determining the mitochondrial activity of the cells after 24-hours incubation.
  • PTX was encapsulated into albumin nanoparticles, with one set of nanoparticles also encapsulating IKR (initial IKR concentration: 20 ⁇ ; expected effective IKR concentration when particles are administered to cells: 5 ⁇ ), and another set just encapsulating the PTX.
  • the formulations were administered to Jurkat cells, to SH-SY5Y cells, and to HL- 60/VCR cells, at equivalent PTX concentrations ranging from 0 to 50 nM. Cell viability was measured by determining the mitochondrial activity of the cells after 24-hours incubation.
  • PTX-nanoparticles were able to reduce cell growth in a dose-dependent manner.
  • the inclusion of IKR in the nanoparticles significantly inhibited cell growth.
  • cell growth was, in practical terms, halted.
  • Suspension cells appeared more sensitive to the treatment, as the growth inhibition for such cells was clearly higher than that observed for SH-SY5Y ( Figure 15).
  • Example 12 Intracellular residence time of doxorubicin is increased in the presence of IKR.
  • HL-60/VCR cells were incubated with doxorubicin (DOX, 50 ⁇ g/ml) for up to 2 hours, in the presence or absence of Rs-ahx-IKR (5 ⁇ ).
  • DOX doxorubicin
  • pGP activity causes its intracellular levels to drop over time. Accordingly, the intracellular levels, as determined by flow cytometry, of DOX decreased in absence of Rs-ahx-IKR. However, they dramatically increased when Rs-ahx-IKR was coadministered. This effect was evident also for liposomal formulations, which comprised either DOX, or both DOX and IKR. However, in that case the increased residence time only became evident after 4 hours of incubation. This is presumably linked to the slower entry of liposomes into cells, and to the non-instantaneous release of DOX from the liposomal vesicles ( Figure 16).
  • Kendarimide A a novel peptide reversing P-glycoprotein-mediated multidrug resistance in tumor cells, from a marine sponge of Haliclona sp. Tetrahedron 60, 7053- 7059.
  • MDR Multidrug resistance
  • Lamellarin D a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux. Cancer Lett 221, 165-175.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des inhibiteurs de la glycoprotéine P, qui sont des composés qui comprennent ou sont constitués d'un tripeptide représenté par la séquence XAB, X, A et B étant 7 acides aminés, X pouvant être n'importe quel acide aminé et A et B étant des acides aminés basiques, destinés à être utilisés dans le traitement d'un trouble. L'invention se rapporte en outre à des compositions comprenant de tels composés et à l'utilisation de tels composés ou de telles compositions dans le traitement d'un trouble. L'invention se rapporte en outre à un procédé permettant d'inhiber la glycoprotéine P dans sa capacité à exporter des substances d'une cellule, et à un procédé de traitement d'un trouble, lesdits procédés comprenant l'administration d'un composé ou d'une composition selon l'invention à un sujet. L'invention se rapporte également à une thérapie de combinaison qui utilise des composés ou des compositions selon l'invention en combinaison avec des composés, ou compositions, de l'état de la technique.
PCT/EP2016/067291 2015-07-23 2016-07-20 Nouveaux inhibiteurs de la glycoprotéine p WO2017013172A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15178130.9 2015-07-23
EP15178130 2015-07-23

Publications (1)

Publication Number Publication Date
WO2017013172A1 true WO2017013172A1 (fr) 2017-01-26

Family

ID=53785465

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/067291 WO2017013172A1 (fr) 2015-07-23 2016-07-20 Nouveaux inhibiteurs de la glycoprotéine p

Country Status (1)

Country Link
WO (1) WO2017013172A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11028976B2 (en) 2016-01-28 2021-06-08 EcoSense Lighting, Inc. Illuminating with a multizone mixing cup
US11047534B2 (en) 2016-01-28 2021-06-29 EcoSense Lighting, Inc. Multizone mixing cup illumination system

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197334A1 (en) * 2003-04-02 2004-10-07 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
WO2004087192A1 (fr) * 2003-04-01 2004-10-14 Lipotec, S.A. Compositions pharmaceutiques et cosmetiques permettant de prevenir et de traiter le vieillissement cellulaire au moyen de la sequestration d'especes reactives carbonyle
JP2006225269A (ja) * 2005-02-15 2006-08-31 Yoshihiro Futamura コラゲナーゼ阻害作用を有するトリペプチド、それを含有する発酵物、食品製剤、化粧品製剤
US20070009534A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
DE102008054117A1 (de) * 2008-10-31 2010-05-06 Henkel Ag & Co. Kgaa Wirkstoffkombination zur Behandlung reifer Haut II
WO2011084061A1 (fr) * 2010-01-08 2011-07-14 Universitair Medisch Centrum St. Radboud Cpp (peptide pénétrant les cellules) et ses utilisations
CN102399261A (zh) * 2010-09-07 2012-04-04 任发政 具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物
KR20120048830A (ko) * 2010-11-08 2012-05-16 주식회사 네오디엠 트리 펩타이드 유도체를 함유한 새치 치료제의 제조방법
WO2012143845A2 (fr) * 2011-04-21 2012-10-26 Sederma Nouvelles utilisations cosmétiques et thérapeutiques de tripeptide ghk
KR20140107784A (ko) * 2013-02-28 2014-09-05 주식회사 크라운진 탈모 방지 및 모발 성장 촉진용 조성물
WO2014197008A1 (fr) * 2013-06-03 2014-12-11 Huiwen Liu Préparation et utilisation de nanoparticules et nano-émulsions à composés encapsulés
WO2015061607A1 (fr) * 2013-10-23 2015-04-30 Whitehead Institute For Biomedical Research Modulation de mtorc1 par acides aminés et leurs utilisations

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087192A1 (fr) * 2003-04-01 2004-10-14 Lipotec, S.A. Compositions pharmaceutiques et cosmetiques permettant de prevenir et de traiter le vieillissement cellulaire au moyen de la sequestration d'especes reactives carbonyle
US20040197334A1 (en) * 2003-04-02 2004-10-07 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
JP2006225269A (ja) * 2005-02-15 2006-08-31 Yoshihiro Futamura コラゲナーゼ阻害作用を有するトリペプチド、それを含有する発酵物、食品製剤、化粧品製剤
US20070009534A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism
DE102008054117A1 (de) * 2008-10-31 2010-05-06 Henkel Ag & Co. Kgaa Wirkstoffkombination zur Behandlung reifer Haut II
WO2011084061A1 (fr) * 2010-01-08 2011-07-14 Universitair Medisch Centrum St. Radboud Cpp (peptide pénétrant les cellules) et ses utilisations
CN102399261A (zh) * 2010-09-07 2012-04-04 任发政 具有血管紧张素转化酶c-端选择性抑制活性的三肽及其应用和组合物
KR20120048830A (ko) * 2010-11-08 2012-05-16 주식회사 네오디엠 트리 펩타이드 유도체를 함유한 새치 치료제의 제조방법
WO2012143845A2 (fr) * 2011-04-21 2012-10-26 Sederma Nouvelles utilisations cosmétiques et thérapeutiques de tripeptide ghk
KR20140107784A (ko) * 2013-02-28 2014-09-05 주식회사 크라운진 탈모 방지 및 모발 성장 촉진용 조성물
WO2014197008A1 (fr) * 2013-06-03 2014-12-11 Huiwen Liu Préparation et utilisation de nanoparticules et nano-émulsions à composés encapsulés
WO2015061607A1 (fr) * 2013-10-23 2015-04-30 Whitehead Institute For Biomedical Research Modulation de mtorc1 par acides aminés et leurs utilisations

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BUFFONI ET AL: "Skin wound healing properties of synthetic analogues of the tripeptide GHK (GLY-HIS-LYS)", PHARMACOLOGICAL RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 31, January 1995 (1995-01-01), pages 69, XP022358658, ISSN: 1043-6618, DOI: 10.1016/1043-6618(95)86534-9 *
DATABASE WPI Week 200660, Derwent World Patents Index; AN 2006-583260, XP002745608 *
DATABASE WPI Week 201245, Derwent World Patents Index; AN 2012-E42418, XP002745607 *
DATABASE WPI Week 201312, Derwent World Patents Index; AN 2012-G12397, XP002745609 *
DATABASE WPI Week 201468, Derwent World Patents Index; AN 2014-R59544, XP002745610 *
I. I. BOBYNTSEV ET AL: "Anxiolytic Effects of Gly-His-Lys Peptide and Its Analogs", BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 158, no. 6, April 2015 (2015-04-01), US, pages 726 - 728, XP055219116, ISSN: 0007-4888, DOI: 10.1007/s10517-015-2847-3 *
LAI Y ET AL: "Design and synthesis of a potent peptide containing both specific and non-specific cell-adhesion motifs", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 31, no. 18, June 2010 (2010-06-01), pages 4809 - 4817, XP027013399, ISSN: 0142-9612, [retrieved on 20100416] *
POHUNKOVA H ET AL: "Morphological features of bone healing under the effect of collagen-graft-glycosaminoglycan copolymer supplemented with the tripeptide Gly-His-Lys", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 17, no. 16, August 1996 (1996-08-01), pages 1567 - 1574, XP004032962, ISSN: 0142-9612, DOI: 10.1016/0142-9612(95)00310-X *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11028976B2 (en) 2016-01-28 2021-06-08 EcoSense Lighting, Inc. Illuminating with a multizone mixing cup
US11047534B2 (en) 2016-01-28 2021-06-29 EcoSense Lighting, Inc. Multizone mixing cup illumination system

Similar Documents

Publication Publication Date Title
Zhang et al. Drug development targeting the ubiquitin–proteasome system (UPS) for the treatment of human cancers
Jin et al. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
Papo et al. Suppression of human prostate tumor growth in mice by a cytolytic d-, l-amino acid peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion
Liu et al. D‐peptides as recognition molecules and therapeutic agents
Webster et al. Complement component C1q modulates the phagocytosis of Aβ by microglia
Zhang et al. Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells
Liu et al. Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery
Ikonomopoulou et al. Gomesin inhibits melanoma growth by manipulating key signaling cascades that control cell death and proliferation
JP5657549B2 (ja) 癌の阻害剤としてのｍｕｃ−１細胞質ドメインペプチド
Boohaker et al. Rational development of a cytotoxic peptide to trigger cell death
Patra et al. Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer
US20120135914A1 (en) Etoposide and doxorubicin conjugates for drug delivery
Gajula et al. A synthetic dolastatin 10 analogue suppresses microtubule dynamics, inhibits cell proliferation, and induces apoptotic cell death
US8119601B2 (en) Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
Kim et al. The insect peptide CopA3 increases colonic epithelial cell proliferation and mucosal barrier function to prevent inflammatory responses in the gut
Tørfoss et al. Synthesis of anticancer heptapeptides containing a unique lipophilic β2, 2‐amino acid building block
Li et al. Smac therapeutic peptide nanoparticles inducing apoptosis of cancer cells for combination chemotherapy with doxorubicin
Tian et al. Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis
US20130210749A1 (en) Peptides, constructs and uses therefor
Hilchie et al. Enhanced killing of breast cancer cells by a d-amino acid analog of the winter flounder-derived pleurocidin NRC-03
Patel et al. Novel cell-penetrating peptide conjugated proteasome inhibitors: anticancer and antifungal investigations
WO2017013172A1 (fr) Nouveaux inhibiteurs de la glycoprotéine p
Tong et al. Targeted degradation of alpha-Synuclein by autophagosome-anchoring chimera peptides
US8143222B2 (en) Modular platform for targeted therapeutic delivery
US20120214741A1 (en) Vdac1 compositions and methods of use thereof for regulating apoptosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16741926

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16741926

Country of ref document: EP

Kind code of ref document: A1